Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 5:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 66 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Steroid Refractory Graft Versus Host Disease Clear all
Completed Phase 1 Interventional

Evaluation of Umbilical Cord-Derived Wharton's Jelly Stem Cells for the Treatment of Acute Graft Versus Host Disease

NCT03158896
View directory record Official record
Conditions
Acute Graft Versus Host Disease
Interventions
MSCTC-0010 Dose Escalation
Biological
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 4, 2026, 5:18 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Adult Human Mesenchymal Stem Cells to Treat Steroid Refractory Acute Graft Versus Host Disease (GVHD)

NCT00366145
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
Prochymal®, Placebo, Standard of Care for GVHD
Biological · Drug
Lead sponsor
Mesoblast, Inc.
Industry
Eligibility
6 Months to 70 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
47
States / cities
Birmingham, Alabama • Tucson, Arizona • Duarte, California + 35 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2022 · Synced Oct 4, 2026, 5:18 AM EDT
Completed Phase 3 Interventional Results available

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

NCT03112603
View directory record Official record
Conditions
Graft-versus-host Disease (GVHD)
Interventions
Ruxolitinib, Extracorporeal photopheresis (ECP), Low-dose methotrexate (MTX), Mycophenolate mofetil (MMF), mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus), Infliximab, Rituximab, Pentostatin, Imatinib, Ibrutinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
38
States / cities
Tucson, Arizona • Duarte, California • La Jolla, California + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Oct 4, 2026, 5:18 AM EDT
Completed Phase 2 Interventional Results available

A Proof of Concept Pilot Trial of Alpha-1-Antitrypsin for Pre-Emption Of Steroid-Refractory Acute GVHD

NCT03459040
View directory record Official record
Conditions
Graft-versus-host-disease, GVHD
Interventions
Alpha 1-Antitrypsin
Drug
Lead sponsor
John Levine
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
5
States / cities
Duarte, California • Boston, Massachusetts • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2021 · Synced Oct 4, 2026, 5:18 AM EDT
Completed Phase 1 Interventional Results available

Ultra-Low Dose Interleukin-2 for Refractory Chronic Graft Versus Host Disease

NCT00529035
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
Interleukin-2
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 1, 2020 · Synced Oct 4, 2026, 5:18 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

In-vivo Regulatory T Cell Enhancement With Cyclophosphamide and Sirolimus

NCT01453140
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
Cyclophosphamide and Sirolimus, Low dose IL-2 with Cytoxan + Sirolimus, Low dose IL-2, low dose Vidaza, cyclophosphamide & Sirolimus, Low dose IL-2, Vidaza, Cytoxan & Sirolimus
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years to 70 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 4, 2026, 5:18 AM EDT
Terminated Not applicable Interventional Results available

Efalizumab in Treating Patients With Graft-Versus-Host Disease of the Skin That Did Not Respond to Previous Steroids

NCT00489216
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
efalizumab
Biological
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 23, 2017 · Synced Oct 4, 2026, 5:18 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host Disease

NCT02195869
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
Ibrutinib
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
10
States / cities
Duarte, California • San Francisco, California • Stanford, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2019 · Synced Oct 4, 2026, 5:18 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Abatacept to Treat Steroid Refractory Chronic Graft Versus Host Disease (cGVHD)

NCT01954979
View directory record Official record
Conditions
Chronic Graft Versus Host Disease
Interventions
Abatacept
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 4, 2026, 5:18 AM EDT
Completed Phase 2 Interventional

Thalidomide in Treating Patients With Chronic Graft-Versus-Host Disease Following Bone Marrow Transplant

NCT00003894
View directory record Official record
Conditions
Graft Versus Host Disease, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
thalidomide
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
3 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
10
States / cities
Little Rock, Arkansas • Kansas City, Kansas • New Orleans, Louisiana + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2011 · Synced Oct 4, 2026, 5:18 AM EDT
Completed Phase 1 Interventional

A Pilot Study of Imatinib Mesylate in Steroid Refractory Chronic Graft Versus Host Disease

NCT00760981
View directory record Official record
Conditions
Graft vs Host Disease
Interventions
Imatinib
Drug
Lead sponsor
David Miklos
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
2
States / cities
Stanford, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 15, 2020 · Synced Oct 4, 2026, 5:18 AM EDT
Completed Phase 2 Interventional Results available

Extracorporeal Photopheresis and Low Dose Aldesleukin in Treating Patients With Steroid Refractory Chronic Graft-Versus-Host Disease

NCT03007238
View directory record Official record
Conditions
Chronic Graft Versus Host Disease
Interventions
Aldesleukin, Extracorporeal Photopheresis, Laboratory Biomarker Analysis, Quality-of-Life Assessment
Biological · Procedure · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Apr 8, 2024 · Synced Oct 4, 2026, 5:18 AM EDT
Not listed Phase 2 Interventional

Bortezomib for the Treatment of Refractory Chronic Graft-vs-Host Disease(cGVHD)

NCT01158105
View directory record Official record
Conditions
Chronic Graft-versus-host Disease
Interventions
Bortezomib
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 18, 2016 · Synced Oct 4, 2026, 5:18 AM EDT
Active, not recruiting Phase 1 Interventional

Trial of Regulatory T-cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease

NCT01937468
View directory record Official record
Conditions
Chronic Graft Versus Host Disease, Chronic GVHD, Complications of Organ Transplant Stem Cells
Interventions
Treg-enriched infusion, Interleukin-2
Other · Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 4, 2026, 5:18 AM EDT
Terminated Phase 3 Interventional Results available

Methoxsalen and Extracorporeal Photopheresis (ECP) for the Treatment of Pediatric Participants With Steroid Refractory Acute Graft Versus Host Disease

NCT02524847
View directory record Official record
Conditions
Steroid Refractory Acute Graft Versus Host Disease
Interventions
Methoxsalen, Extracorporeal Photopheresis (ECP)
Drug · Procedure
Lead sponsor
Therakos, Inc., a Mallinckrodt Company
Industry
Eligibility
1 Year to 21 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
17
States / cities
Phoenix, Arizona • Los Angeles, California • New Haven, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2020 · Synced Oct 4, 2026, 5:18 AM EDT
Completed Phase 3 Interventional Results available

Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Participants With New Onset Chronic Graft Versus Host Disease (cGVHD)

NCT02959944
View directory record Official record
Conditions
Chronic Graft Versus Host Disease
Interventions
ibrutinib, Placebo, Prednisone
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
12 Years and older
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
38
States / cities
Scottsdale, Arizona • Palo Alto, California • San Francisco, California + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2023 · Synced Oct 4, 2026, 5:18 AM EDT
Completed Phase 2 Interventional Results available

A Pilot Study of Alpha-1-Antitrypsin (AAT) in Steroid Refractory Acute Graft vs Host Disease

NCT01700036
View directory record Official record
Conditions
Graft vs Host Disease
Interventions
Alpha-1-Antitrypsin (AAT)
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
2
States / cities
Boston, Massachusetts • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 27, 2018 · Synced Oct 4, 2026, 5:18 AM EDT
Terminated Phase 2 Interventional Results available

Vismodegib in Treating Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease

NCT02337517
View directory record Official record
Conditions
Chronic Graft Versus Host Disease
Interventions
Laboratory Biomarker Analysis, Vismodegib
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Ann Arbor, Michigan • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 19, 2021 · Synced Oct 4, 2026, 5:18 AM EDT
Recruiting Phase 1 Interventional

Ruxolitinib Plus Fostamatinib for Steroid Refractory cGvHD

NCT06233110
View directory record Official record
Conditions
Chronic Graft Versus Host Disease
Interventions
Fostamatinib, Ruxolitinib
Drug
Lead sponsor
Stefanie Sarantopoulos, MD, PhD.
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 4, 2026, 5:18 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Tocilizumab for Treatment of Steroid Refractory Acute Graft-versus-Host Disease

NCT01475162
View directory record Official record
Conditions
Acute Graft Versus Host Disease
Interventions
Tocilizumab
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Oct 4, 2026, 5:18 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Daily IL-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease

NCT01366092
View directory record Official record
Conditions
Chronic Graft-versus-host Disease
Interventions
Interleukin-2
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 4, 2026, 5:18 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies

NCT05327023
View directory record Official record
Conditions
Hematologic Neoplasms
Interventions
donor lymphocyte infusion, Cyclophosphamide, Busulfan, Mycophenolate mofetil, Fludarabine, Sirolimus
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years to 120 Years
Enrollment
430 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 4, 2026, 5:18 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Trial of Low-Dose Interleukin-2 (IL-2) Added to Extra-Corporeal Photopheresis for Steroid-Refractory cGVHD

NCT02340676
View directory record Official record
Conditions
Chronic Graft-versus-host-disease
Interventions
Extracorporeal Photopheresis (ECP), Interleukin-2
Procedure · Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 4, 2026, 5:18 AM EDT
Terminated Phase 1 Interventional

Phase I Trial of LDE225 for Steroid-refractory Chronic GVHD After Allogeneic HSCT

NCT02086513
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
LDE225
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 19, 2018 · Synced Oct 4, 2026, 5:18 AM EDT